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Optimization of a “bump-and-hole” approach to
allele-selective BET bromodomain inhibition†
A. C. Runcie, ‡a M. Zengerle,‡a K.-H. Chan, ‡a A. Testa,a L. van Beurden,a
M. G. J. Baud, a O. Epemolu,a L. C. J. Ellis,a K. D. Read,a V. Coulthard,b A. Brienb
and A. Ciulli *a
Allele-speciﬁc chemical genetics enables selective inhibition within families of highly-conserved proteins.
The four BET (bromodomain & extra-terminal domain) proteins – BRD2, BRD3, BRD4 and BRDT bind
acetylated chromatin via their bromodomains and regulate processes such as cell proliferation and
inﬂammation. BET bromodomains are of particular interest, as they are attractive therapeutic targets but
existing inhibitors are pan-selective. We previously established a bump-&-hole system for the BET
bromodomains, pairing a leucine/alanine mutation with an ethyl-derived analogue of an established
benzodiazepine scaﬀold. Here we optimize upon this system with the introduction of a more
conservative and less disruptive leucine/valine mutation. Extensive structure–activity-relationships of
diverse benzodiazepine analogues guided the development of potent, mutant-selective inhibitors with
desirable physiochemical properties. The active enantiomer of our best compound – 9-ME-1 – shows
200 nM potency, >100-fold selectivity for the L/V mutant over wild-type and excellent DMPK
properties. Through a variety of in vitro and cellular assays we validate the capabilities of our optimized
system, and then utilize it to compare the relative importance of the ﬁrst and second bromodomains to
chromatin binding. These experiments conﬁrm the primacy of the ﬁrst bromodomain in all BET proteins,
but also signiﬁcant variation in the importance of the second bromodomain. We also show that, despite
having a minor role in chromatin recognition, BRD4 BD2 is still essential for gene expression, likely
through the recruitment of non-histone proteins. The disclosed inhibitor:mutant pair provides a powerful
tool for future cellular and in vivo target validation studies.
Introduction
Chemical probes are biologically-active small-molecules (typi-
cally inhibitors) that are used to investigate the importance and
functions of proteins.1–3 The use of chemical probes and obser-
vation of the resulting phenotypes in this fashion is known as
chemical genetics. Although possessing various advantages over
classical genetics (such as gene knockouts) chemical genetics
requires that any probes used have a well-dened mode of action
and high-selectivity for their target proteins. In cases where target
proteins are not structurally distinct enough for the development
of selective probes more advanced techniques are needed.
The ‘bump-&-hole’ system is a way of engineering selective
inhibition of structurally conserved proteins through the
generation of orthogonal protein:ligand pairs.4 In this system
existing small-molecule inhibitors, showing high aﬃnity and
desirable DMPK properties, are modied to include a steric
‘bump’ that weakens or abolishes binding to the target wild-
type proteins. Simultaneously, a reciprocal mutation is intro-
duced to the target, replacing a large amino acid residue with
a smaller one to create a ‘hole’ that can accommodate the
bumped ligand. Using this approach one can take a pan-
selective inhibitor that binds multiple structurally-related
proteins and generate a bumped ligand that will only inhibit
a target protein that has been mutated to contain a ‘hole’. This
system allows the specic inhibition of multiple proteins
without the costly design of multiple target-specic chemical
probes, and takes advantage of existing chemical tools to bypass
the discovery of a high-quality chemical scaﬀold. Such engi-
neered selectivity has successfully been applied to protein
kinases and ATP-competitive inhibitors5 and FKBP-targeting
chemical dimerizers.6,7 The bump-&-hole approach has not
previously been applied to any inhibitor of epigenetic proteins,
but the use of mutant enzymes and modied co-factors has
been used on a number of epigenetic enzymes for target
identication.1,4,8,9
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In previous work we have explored the potential for estab-
lishing a bump-&-hole system targeting the bromodomains of
the BET (bromo and extra-terminal) protein family.10,11 These
four human proteins – BRD2, BRD3, BRD4 and BRDT – each
contain two tandem bromodomains that bind acetylated lysine
residues in histone tails, leading to the recruitment of multi-
protein complexes to chromatin.12,13 Through this function
the BET proteins play a signicant role in controlling tran-
scription and regulating gene expression.14–16 The BET proteins
regulate proliferation, the cell-cycle and cell diﬀerentiation in
a wide array of contexts and they have been associated with
many disease states such as cancer, inammation, HIV infec-
tion and neurological disorders.17
In the last decade many high-quality small-molecule inhib-
itors of BET bromodomains have been developed (Chart 1),
both for therapeutic and research purposes.18–22 The phenotypes
generated by said inhibitors have been used to investigate the
functions of BET proteins and their signicance as therapeutic
targets. This process has been limited by the pan-selective
nature of the BET inhibitors, as they typically target all BET
bromodomains with similar potency,10 hence specic proteins/
bromodomains cannot be associated to specic phenotypes.1–3
Furthermore this pan-selectivity increases the possibility of
side-eﬀects limiting the usability of therapeutic BET inhibitors
as all four BET proteins will be inhibited when only one may be
disease-relevant.23 Additionally it is becoming increasingly
apparent that the phenotypes generated by non-BET bromo-
domain inhibitors is in part driven by low-level BRD4 inhibi-
tion.24–27 Recently some advances have been made, as several
inhibitors have been reported to be mildly selective for the
‘second’ bromodomains (BD2s)11,28,29 or the ‘rst bromodo-
mains (BD1s)30 of the BET proteins. One recently reported
compound showed >10-fold selectivity for BRD4 BD1, through
exploiting the diﬀering dynamics of the ZA loop between
diﬀerent bromodomains.31 The BET bromodomains have also
been successfully targeted for degradation by bifunctional
PROTAC (proteolysis targeting chimera) compounds, based on
existing BET inhibitor scaﬀolds32–35 and novel scaﬀolds.36 In our
research we discovered a series of PROTACs that are BRD4-
selective through the exploitation of novel protein–protein
interactions between BRD4 and the VHL ubiquitin E3 ligase.37
For our bump-&-hole project10 we have previously identied
a conserved leucine residue in the BET bromodomains binding
site (L94 & L387 in BRD4) that can be substituted with an alanine,
yielding relatively stable and functional bromodomain mutants.
Compound ET – an I-BET762 (ref. 19)/JQ1 (ref. 18)-related
benzodiazepine scaﬀold bearing an ethyl bump – targets the L/A
mutation with high-aﬃnity and 100-fold selectivity relative to
wild-type (Fig. 1A). We have since worked to optimize, validate
and implement this system. Although still capable of binding
acetylated histone peptides the L/A mutants show a noticeable
loss in binding aﬃnity, and if not functional enough may
compromise the viability of mutant cell-lines and animal models
Chart 1 Benzodiazepine-based BET inhibitors.
Fig. 1 Bump-&-hole system optimization. (A) Co-crystal structure of
ET bound to BRD2 BD2 L383A (4QEW). (B) Comparison of WT leucine
and mutated residues. (C) Scaﬀold of bumped compounds, with
modiﬁcation sites highlighted.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2452–2468 | 2453
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(Fig. 1B). Additionally, screening of diverse chemical modica-
tions may deliver optimized inhibitors that are more selective
and have improved physiochemical properties (Fig. 1C).
Results
An optimised leucine/valine mutation displays high structural
& functional conservation
Here we explored the possibility of improving the bump-&-hole
system through replacement of the previously described10 and
potentially problematic L/A mutation (L94 and L387 in BRD4)
(Fig. S1†). Through structural analysis of the bromodomain we
hypothesized that a leucine/valine substitution (L/V) would be
a more conservative change than the previous L/A substitution,
resulting in a smaller ‘hole’ but still allowing enough space to
accommodate a bumped ligand.
The mutant BET bromodomains were puried as single-
bromodomain constructs, following site-directed mutagenesis,
for in vitro characterization. This characterization focused on the
ability of the bromodomains to bind and discriminate between
acetylated histone peptides. We used diﬀerential scanning uo-
rimetry (DSF) to show that the BET bromodomain constructs
were not destabilized by the L/V mutation (Table S1†).
We next assessed how the L/V mutation impacted the ability
of the bromodomains to bind acetylated histone peptides. We
used isothermal titration calorimetry (ITC) to measure the
aﬃnity and thermodynamic parameters for di-acetylated
H4K(5,8)ac and tetra-acetylated H4K(5,8,12,16)ac substrate
peptides12 binding to BET bromodomain constructs. The L/V
mutation typically decreased the aﬃnity of the peptide:-
bromodomain interaction by around two-fold (Table S2†),
which is close to experimental errors and a signicant
improvement over the L/A mutation which showed up to 10-fold
decreases in aﬃnity.10 The supremacy of L/V over L/A was
conrmed by titrations of H4K(5,8,12,16)ac against BRD2 BD1
and BRD4 BD1 L/A (Fig. 2A). Analysis of the thermodynamic
parameters of binding (DH, TDS, DG) suggested that the L/V
mutation does not substantially impact the binding mode of
these peptides. In contrast, changes in these parameters relative
to wild-type were much greater for the L/A mutation, consistent
with a more detrimental eﬀect (Fig. S2†).
The cellular function of the BET proteins is based not just on
how strongly they bind histone peptides with specic epigenetic
marks but also on what combinations of marks they recognize.
To assess the impact of the L/Vmutation on the binding proles
of the BET bromodomains we used bio-layer interferometry
(BLI) to screen a library of acetylated histone peptides (Fig. 2B).
Both WT and L/V bromodomains showed a marked preference
for a cluster of poly-acetylated H4 peptides, especially H4K(5,8)
ac, H4K(5,8,12)ac and H4K(5,8,12,16)ac. The WT and L/V
binding proles for all BD1s were virtually identical; and over-
all the L/V mutation had a visibly smaller eﬀect on peptide
recognition than the L/A mutant.10 No signicant binding was
observed for any non-H4 peptides (Fig. S3†).
To better understand how the L/V mutation aﬀects histone
binding, the X-ray crystal structure of the apo form of BRD2 BD2
L383V was solved and compared to the previously solved
structures of WT and L383A BRD2 BD2 (ref. 10). Both the L/V
and L/A mutants retain the overall structure of WT BRD2 BD2.
The conformation of the ZA loop in the L/V mutant structure
superposes very well with that of the WT (so-called “open”
conformation), which diﬀers from that observed in the L/A
mutant, which is in a closed conformation (Fig. 2C). Notably
however, the L/A mutant when ligand-bound had instead an
open ZA loop (ref. 10, Fig. S4†). Re-orienting the ZA loop during
binding might be contributing to the varying aﬃnities observed
between WT and mutant bromodomains for acetylated histone
peptides. However, diﬀerences in crystallization space group
and consequently crystal packing around the ZA loop amongst
the various crystal structures might also contribute to the
diﬀerent conformations observed for the ZA loop.
To assess the functionality of the L/V mutants in a cellular
environment we used a cellular uorescence recovery aer pho-
tobleaching (FRAP) assay tomonitor the interaction between full-
length BET proteins (GFP-tagged) and chromatin inside cells.
Inhibition by ligands or deleterious mutations would reduce the
proportion of GFP-tagged BET proteins bound to chromatin,
increasing the rate of uorescence recovery and decreasing the
measured recovery time (t1/2).10,38 Mutant forms of BRD4 were
compared in this assay and the L/V mutation was shown to have
a much smaller impact on chromatin binding than the L/A
mutation (Fig. 2D), in line with our in vitro data with histone
peptides. Similar results were obtained for the L/V mutants of
BRD2, BRD3 and BRDT (Fig. S5†). Together our biophysical and
cellular data show that the L/V mutation is a major improvement
over the L/A mutation, and has a minor eﬀect on the structure of
the BET bromodomains and their substrate binding properties.
Chemical modications for selective probing of the L/V
bromodomains
In addition to optimizing the ‘biology’ of the bump-&-hole
system (the mutation) we were interested in optimizing the
‘chemistry’ through the design of chemical probes superior in
terms of binding selectivity, potency and DMPK properties.
First, to cover a range of bump sizes, we included primary
alkyl methyl, ethyl and propyl as well as allyl ‘bump’ modica-
tions. As the L/V mutation is more subtle than the previous L/A
and is expected to generate a smaller ‘hole’, we decided not to
include more sterically-demanding modications.
Second, we explored the possibility of modifying the core
scaﬀold with the aim to weaken binding to wild-type protein,
potentially more so than against the mutant. Previous SAR
studies on I-BET762 analogues described a number of chemical
modications to the benzodiazepine scaﬀold that resulted in
weaker binding aﬃnities to the WT BET bromodomains.39 One
such modication, the shiing of the methoxy group from the
80 to the 90 position on the fused-phenyl ring, was deemed
attractive as it reduced the BRD4 pIC50 by 0.5 log units and
resulting analogues would retain very similar physicochemical
properties to the parent compounds. We hypothesized that
such a “Methoxy-shi” could enhance selectivity if the resulting
steric clash was better accommodated by the mutated binding
site compared to the WT protein.
2454 | Chem. Sci., 2018, 9, 2452–2468 This journal is © The Royal Society of Chemistry 2018
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Finally, we placed our attention to the exible side chain on
which the alkyl bump is located. Our ‘rst generation’
compoundsME and ET both possess a methylester group at this
position. Co-crystal structures showed the methylester side
chain of ME and ET bound to the L/A mutant moved signi-
cantly compared to the bound conformation of the
Fig. 2 L/V mutant characterization. (A) ITC titrations of tetra-acetylated H4 peptide into BET bromodomains. (B) Binding proﬁles of WT and L/V
bromodomains for acetylated H4 peptides, derived from BLI screen. Responses normalized to strongest response of each construct, and color-
coded. Red ‘K’ in peptide sequence denotes lysine acetylation. (C) Alignment of BRD2 BD2 WT (2DVV), L/V and L/A (4QEU) apo structures, with
leucine/valine/alanine highlighted. (D) Recovery times of GFP-labelled BRD4 constructs following 0.5 s laser bleach event, at 2 mM SAHA and
0.03% DMSO. Each bar is mean and SE of 50 U2OS cells tested over two separate experiments. Statistical signiﬁcance determined with two-
tailed t tests: ns P > 0.05; *P # 0.05, **P # 0.01, ***P # 0.001, ****P < 0.0001.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2452–2468 | 2455
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corresponding ethyl-amide group in I-BET762 bound to the
WT protein.10 Such freedom to rotate could allow the bumped
compound to accommodate itself in the WT binding pocket,
leading to the residual aﬃnity observed for ME and ET against
WT. In contrast, ‘locking’ this side-chain in place would be
expected to further weaken WT binding. We therefore decided
to replace the methyl-ester side-group rst with an amide, as
in I-BET762, which would lock the side-group in place through
a hydrogen bond from the amide NH to the ASN140
residue.19,39 In addition, we decided to include a tert-butyl
ester group, as in JQ1, as this could form favourable hydro-
phobic interactions, and its bulky nature may limit the exi-
bility of the side-chain. The ethyl-amide and tert-butyl ester
side-groups were also deemed as attractive ways to ne-tune
the ADMET and physicochemical properties of our chemical
probes.
Our L/V-selective ‘bumped’ compounds are derived from
analogues of the known BET bromodomain probe, and clinical
trial candidate, I-BET762. The synthesis and SAR of this 1,4-
benzodiazepine scaﬀold is well described in the literature,39
allowing easy access to our scaﬀold I-BET-OMe (1) and its
analogue incorporating the methoxy shi (9-IBET-OMe) (2). The
key stage of the synthesis of all our bumped compounds was the
addition of the sterically demanding alkyl ‘bump’ on the a-
carbon. Potassium hexamethyldisilazane (KHMDS) was used to
deprotonate in the a-position to the acetic acid methyl ester, to
generate the desired enolate intermediate.11 These intermedi-
ates were then reacted with the appropriate alkyl iodides to
form the desired a-alkylated derivatives (3–9) as diastereoiso-
meric mixtures.
From pervious work,10 the biologically active product pres-
ents a 2R*,3S* relative stereochemistry; however the diastereo-
meric mixture was at times inconveniently biased towards the
inactive 2S*3S* diastereomer, which could be formed at an
excess of up to 25-fold. When this occurred the diastereomeric
mixtures were epimerized using sodium methoxide in anhy-
drous methanol under microwave irradiation.
Once the bumped group was installed, aqueous sodium
hydroxide was used to hydrolyze the methyl-ester group and
obtain the free carboxylic acids (10–15). Ethyl and di-ethyl
amide groups (16–22) were introduced using standard peptide
coupling conditions, using 1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexauorophosphate
(HATU) as the coupling reagent and N,N-diisopropylethylamine
(DIPEA) as the amine base. Tert-butyl esters (23–26) were ob-
tained from the carboxylic acids using tert-butyl tri-
chloroacetimidate and boron-triuoride as a catalyst.
All compounds were synthesized as diastereomeric mixtures.
Reverse phase HPLC was then used to obtain pure samples of
the 2R*,3S* diastereoisomer as a racemate, which was expected
to contain the active compound, based on our previous work.10
Individual enantiomers were not separated at this stage of the
project and unless explicitly stated otherwise, ligand concen-
trations and measured Kd and IC50 values refer to the concen-
tration of the active enantiomer, i.e. half the concentration of
the racemate (Scheme 1).
Evaluation & SAR trends of bumped compounds
AlphaLISA & X-ray crystallography. Our compounds were rst
evaluated in a robust and eﬃcient competitive AlphaLISA assay
(Table 1, values for individual bromodomains are in Table S4†).
The assay gave us broad SAR trends and allowed us to disqualify
compounds lacking suﬃcient potency (L/V pIC50 $ 5.9) or
selectivity (DpIC50 $ 1.3). This AlphaLISA assay measured the
displacement from the bromodomain binding pocket of a bio-
tinylated JQ1 probe40 (Bio-JQ1) (Fig. S6†), which we show to be
a potent binder of both WT and L/V BET bromodomains (Fig. S7
& Table S3†). As SAR trends were identied from the data,
a series of compounds showing potential as chemical probes
were co-crystallized with L/V BRD2 BD2 and the resulting crystal
structures used to rationalize experimental observations (X-ray
data collection and renement statistics are in the ESI†).
Our scaﬀold compound 1 was as potent as I-BET762 & (+)JQ1
against WT bromodomains, which was unsurprising given their
structural similarity. Meanwhile, ITC titrations with 1 provided Kd
values of 150 nM and 290 nM for BRD4 BD1 WT and L/V, respec-
tively. Due to the assay's high sensitivity we were able to detect very
weak displacement by the inactive ()JQ1 isomer at high concen-
trations. Several bumped compounds (e.g. 17–22) showed similarly
low potency, which we interpret as them being unlikely to bindWT
BET proteins at commonly used concentrations.
Many of our bumped compounds showed promise as potent
and selective probes of L/V BET bromodomains. Methyl, ethyl
and allyl bumps (3–5), the 90 methoxy group (7–9, 21) and the
ethyl-amide side-group (16–18, 21) typically met our criteria.
Overall this dataset shows the eﬃcacy of the bump-&-hole
approach, with only the propyl bump (6) and tert-butyl ester
compounds (23–26) showing less than 10-fold selectivity.
Moreover, a wide range of selectivity and potency was observed
across the series, showing that the activity of bumped
compounds can be ne-tuned with the right modications.
As expected the addition of alkyl bumps weakened binding
for WT bromodomains and is necessary for L/V selectivity. The
smaller bumps increase potency for L/V bromodomains, as the
bump and hole now form a new hydrophobic interaction. The
eﬀect of the bump on potency mostly results from its size, as
shown by the highly potent 3 binding much more intimately
within the L/V hole (Fig. 3A). With larger bumps, however, the
rotational exibility of the bump becomes important, with the
semi-rigid 5 bump acting more like the equally exible 4 bump
than the 6 bump of similar length.
Shiing the methoxy group to the 90 position (7–9) did not
cause large changes in the L/V potency of bumped compounds,
despite its pronounced eﬀect on the scaﬀold (2). The methoxy
shi only clearly enhanced selectivity when paired with the
methyl bump (7), where it also does not alter the compound
binding orientation (Fig. 3B).
The replacement of the methyl-ester with an amide group
results in a pronounced reduction on WT binding aﬃnities. Co-
crystal structures (Fig. 3C) conrm the formation of the ex-
pected hydrogen bond to Asn140. As this hydrogen bond locks
the bump in an orientation facing the WT leucine residue it
exacerbates the steric clash.
2456 | Chem. Sci., 2018, 9, 2452–2468 This journal is © The Royal Society of Chemistry 2018
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The ethyl-amide side-group and its hydrogen bond does not
reduce potency in non-bumped scaﬀolds, as can be seen with I-
BET762 and 1. Compounds featuring the di-ethyl amide side-
group (19, 20) show greater WT potency and lower selectivity
than ethyl-amide compounds.
An alternative methyl-ester replacement was the tert-butyl
ester group (23–26), present in the BET inhibitor JQ1. This
group had a very deleterious eﬀect on selectivity, as it both
increased WT potency and reduced L/V potency. Co-crystal
structures (Fig. 3D) of BRD2 BD2 L/V bound to 5 and 24 show
that the tert-butyl group clashes with Leu381, reducing L/V
potency. As this clash pushes the ligand away from the ZA
loop it may relieve the bump/leucine steric clash and increase
WT potency.
DMPK triage
The AlphaLISA screen suggested several promising compounds
showing high potency for L/V bromodomains and selectivity
against WT. A secondary triage of the compounds, investigating
their DMPK qualities, was conducted to eliminate potential
candidates with poor PK properties that would later undermine
their utility as chemical probes in cells and in vivo. To proceed
beyond this triage compounds were required to show no
breakdown in plasma, microsomal clearance rates similar or
lower than existing BET probes and high apparent permeability
(>10 nm s1).
Pleasingly, all bumped compounds were very stable in
plasma (half-lives over 3 hours), while the scaﬀold compounds
(1, 2) had lower stability, likely due to esterase activity (Table 1).
This is consistent with the theory that the presence of an alkyl
bump on the a-carbon is important to increase the ester group
stability, and suggested that replacement of the methyl-ester
side-group was not necessary. Unlike in plasma, 1 and 2 were
found to be very stable in liver microsomes, showing low
intrinsic clearance, which is an indicator of low CYP450
metabolism.41 Compounds bearing the methoxy shi and ethyl-
amide side-group showed very little clearance, while the
hydrophobic tert-butyl ester (23–26) and di-ethyl-amide side
Scheme 1 Bumped compound synthesis. (a) KHMDS, R-I, THF, 78–25 C, 18 h, 24–56%; (b) NaOH, H2O, MeOH, 80 C, 30 min, quant.; (c)
HATU, DIPEA, NH2Et in THF, DCM, 25 C, 2 h, 42–64%; (d) tert-butyl trichloro acetimidate, BF3*Et2O, DCM, 25 C, 14–22%; for detailed synthetic
procedures see ESI.†
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2452–2468 | 2457
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groups (19, 20) produced unacceptably high (>30 ml min1 g1)
clearance rates (Table 1).
Compounds that had passed previous selection criteria,
and others still deemed of interest, were then tested in the in
vitro PAMPA assay (Table 1), an articial model of cell
permeability. All tested compounds with a methyl-ester side-
group (1, 3–9) show extremely high permeability, with Pe
values between 127 and 185 nm s1, whereas those
compounds with the ethyl-amide side-group (16–18, 21, 22)
show 25 to 59 nm s1. The PAMPA and microsomal clearance
data conrms our hypothesis that compound DMPK proper-
ties could be tuned through side-group modications while
altering the position of the methoxy group has little impact on
DMPK properties.
Fig. 3 Compound modiﬁcations & BRD:ligand co-crystal structures. (A) comparison of alkyl bumps; (B) eﬀect of methoxy shift; (C) eﬀect of
ethyl-amide group; (D) eﬀect of tert-butyl ester. Structural alignments of diﬀerent bumped-compounds co-crystallizedwith BRD2 BD2 L/V. Dark
grey dashes represent hydrogen bonds. Other dashes show inter-atomdistances of interest. Ca¼ alpha carbon of valine or other residue. C2¼ 20
carbon of compound. Cester ¼ carbon following ester bond.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2452–2468 | 2459
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Full ITC proles
To nally determine the best bumped compound(s) a small
number of compounds were titrated against all somatic BET
bromodomains, WT and L/V, in ITC (Table 1). The following
compounds met the selection criteria for both the AlphaLISA
assay and DMPK triage and hence underwent ITC proling: 4, 5,
7, 8, 16, 17 and 21. Results for specic bromodomains can be
found in Table S5.†
9-ME (7) and 9-ET (8) were clearly the most promising, with
selectivity values >100-fold, and their ITC proles were repli-
cated until reliable values of potency and selectivity could be
generated. 7 is more potent against both L/V and WT bromo-
domains, while 8 shows greater overall selectivity (Table S6†). 7
was used for the majority of our cellular experiments, as it was
the most potent compound to show >100-fold selectivity and
has slightly better DMPK properties.
The remaining compounds were not as promising, but are
likely still usable as allele-selective inhibitors, and could be
preferable in certain contexts. 4 and 16 show very high potency,
while 17 was the only compound to show no detectable binding
to any WT BET bromodomain.
Validation of bump-&-hole system
The ability of the bump-&-hole system to target a single bro-
modomain, within one BET protein, was shown through ITC
titrations of 4 against BRD2 constructs containing both bro-
modomains. Through measurements of the ligand:protein
stoichiometry it was conrmed that 4 bound with a 2 : 1 stoi-
chiometry when both bromodomains were mutated, and 1 : 1
stoichiometry to the single-bromodomain mutants. Further-
more negligible WT binding was observed (Fig. 4A).
To test the potency and selectivity of our bumped
compounds in cells we used a uorescence recovery aer pho-
tobleaching (FRAP) assay, using U2OS cells over-expressing
GFP-labelled full-length BET proteins.10,38 While the BET
proteins are active and bound to chromatin uorescence
recovery times can be several seconds long. However, when the
proteins are displaced by compounds and freely diﬀusing in the
Fig. 5 Enantiomer Characterization. Puriﬁed 7 enantiomers, and
racemic mixture thereof, titrated against BRD4 BD1 L/V in competitive
AlphaLISA assay (A) and ITC (B).
Fig. 4 Bumped compounds can inhibit single bromodomains and are
eﬀective in cells. (A) ITC titrations of 4 into BRD2 tandem constructs
containing both bromodomains. (B) Eﬀects of range of compounds on
ﬂuorescence recovery of GFP-labelled BRD4 constructs in U2OS cells,
following 0.5 s laser bleach event, at 1 mM compound, 2 mM SAHA and
0.03% DMSO. Statistical signiﬁcance determined with two-tailed t
tests: ns P > 0.05; *P# 0.05, **P# 0.01, ***P# 0.001, ****P < 0.0001.
2460 | Chem. Sci., 2018, 9, 2452–2468 This journal is © The Royal Society of Chemistry 2018
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nucleus the uorescence recovers much faster. The HDAC
inhibitor suberoylanilide hydroxamic acid (SAHA) was used to
increase the assay window by increasing chromatin acetylation
and thus reducing the levels of ‘free’ GFP-BET protein (Fig. S9†).
Several compounds were tested against WT and L/V BRD4
(Fig. 4B) and were shown to enter cells and displace full-length
BET proteins from chromatin in an L/V-selective manner. 7 was
conrmed to be potent and selective in cells, and this
compound was hence used further.
Enantiomer separation
At this point in the project, with the best compounds identied, it
was decided to separate the two enantiomers from our racemic
mixtures. A method for said separation was developed by Reach
Separations Ltd. Racemic mixtures were dissolved to 20 mg ml1
in ethanol and puried by HPLC, using a Lux A1 column
(21.2 mm  250 mm, 5 mm) at ambient temperature and a ow
rate of 21 ml min1. Samples were injected at a volume of 1 ml
with 4 : 6 HEPT : EtOH (0.1% v/v NH3). A 42 mg sample of 7 at
96% purity could be separated into two clear peaks. The rst peak
to elute yielded 11 mg of compound (chemical purity of 94% and
enantiomeric excess of 98), while the second peak yielded 9 mg,
at 98% purity and enantiomeric excess of 97.
Separated enantiomers were next titrated against BRD4 BD1
in the AlphaLISA assay (Table S7†). The compound in the rst
elution peak was more potent than the racemic mixture, and
even more so than the compound eluted in the second peak
(Fig. 5A). We can assign the active enantiomer as (2R,3S)-7, and
consequently the less active enantiomer as (2S,3R)-7. This
assignment is based on analyses of the co-crystal structures. In
all structures obtained, electron density around the chiral
centres in question was well resolved (Fig. S10†). All ligands
could be tted with high quality (ligand real space correlation
coeﬃcient $0.87 and real space R-value #0.18). Based on these
analyses, we therefore conclude that the (2R,3S) enantiomer is
the more active compound.
Fig. 6 (2R,3S)-7: a potent and highly-selective bumped BET inhibitor. (A) Chemical structure of (2R,3S)-7. (B) Co-crystal structure of (2R,3S)-7
bound to BRD2 BD2 L/V, with key residues highlighted. (C) SAR of scaﬀold (1), 7 and (2R,3S)-7. (2R,3S)-7 AlphaLISA data and 1 ITC data from BRD4
BD1 only, other data is mean  SD of titrations against all somatic BET bromodomains. (D) Selectivity plot of (2R,3S)-7.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2452–2468 | 2461
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ITC titrations (Table S8†) showed the (2R,3S) enantiomers of
7 and 8 to bind BRD4 BD1 L/V with high aﬃnity and a 1 : 1
stoichiometry, while the racemic mixtures showed 2-fold
decreases in aﬃnity and enthalpy and N values close to 2
(Fig. 5B), consistent with only half the mixture binding the
bromodomain. Finally no detectable binding was observed for
the (2S,3R) enantiomers.
Although the inactivity of the second enantiomer means
racemic mixtures can still be reliably used in experiments we
chose to exclusively use the active enantiomer going forward.
ITC titrations (Fig. S11†) showed (2R,3S)-7 to be in general more
potent and mutant-selective than the racemic mixture. The use
of the puried active enantiomer overall boosts potency and
selectivity and reducing the total compound concentration by
half will provide other benets (easier dosing, reduced
compoundmetabolism). We therefore present 9-ME-1 (Fig. 6) as
our preferred bumped inhibitor, showing high potency, selec-
tivity for L/V BET bromodomains and a strong DMPK prole.
The (2S,3R) enantiomer – 9-ME-2 – can also be used as an
inactive control.
WT cytotoxicity
To conrm that our bumped compounds will not inhibit WT
BET proteins at commonly used concentrations, nor alter the
phenotypes of BET-sensitive cells we assayed the activity of our
compounds on the viability of BET-dependent AML cell-lines
MV4-11 and HL-60 (ref. 14) (Fig. 7). Pleasingly, (2R,3S)-7
aﬀected these cell-lines at a similar level to the ‘inactive’ ()JQ1
control, and showed no cytotoxicity below 1 mM. This data
supports the use of (2R,3S)-7 for allele-selective BET inhibition
at commonly used concentrations (100 nM–1 mM).
Oﬀ-target screening
We have used several techniques to show that our bumped
compounds are strongly selective for L/V BET bromodomain
mutants. To show selectivity against non-BET WT bromodo-
mains we employed the BROMOscan screen (DiscoveRX),
testing 32 human bromodomains (Fig. S12†). Using BROMO-
scan technology we rst tested our scaﬀold (1) as a positive
control. Against BRD4 BD1WT this gave a Kd value of 15 nM and
showed >90% inhibition above 100 nM. (2R,3S)-7 was screened
at 1 mM and was found to bind non-BET bromodomains to
a lesser degree than BET bromodomains. Some overlap was
observed for SMARCA2, SMARCA4 and WDR9 BD2, an identi-
ed oﬀ-target of JQ1 (ref. 18).
To check for any unexpected oﬀ-target activity outside of the
BET bromodomain subfamily we employed two high-quality
screens. A screen of 50 representative human kinases showed
no more than 20% inhibition at 1 mM (2R,3S)-7 (Table S9†). A
test of 55 receptors, transporters and ion channels (Table S10†)
showed 20% or less inhibition at 1 mM (2R,3S)-7, with the
exception of the melatonin receptor MT1 which showed 77%
inhibition. Undergoing the same screen, JQ1 also had previ-
ously shown oﬀ-target inhibition of MT1, in addition to the
adenosine A3 receptor and the neurokinin NK2 receptor.18
Application to a biological question
Some aspects of basic BET protein function are still unclear,
such as the roles and relative importance of the rst and second
bromodomains within each protein. The BD1 of BRD4 has long
been thought12 to play a greater role in chromatin binding than
its BD2. Experiments with ChIP-seq and acetylated nucleosome
libraries42 show that BRD4 BD1 is alone suﬃcient for chromatin
binding, although it is enhanced by the BD2, while we have
previously shown the BD1 of BRD4 is required for chromatin
binding.10 Recently it was shown that only the BD1 of BRDT is
capable of binding acetylated nucleosomes, and the role of the
BD2 may instead be to recruit acetylated non-histone proteins.43
Currently little is known about the mechanisms of BRD2/BRD3
chromatin binding and the relative importance of their BD1s
and BD2s.
Our development of the highly selective (2R,3S)-7 probe and
improved L/V mutation motivated the application of the bump-
&-hole system to answer these biological questions. By testing
(2R,3S)-7 against GFP-BET constructs in our FRAP assay and
comparing its eﬀects on BD1 vs. BD2 mutants we can observe
their relative importance to chromatin binding. A dose of
200 nM was chosen as it showed no statistically signicant
blockade of WT BRD4 alongside almost complete displacement
of L/V BRD4 (Fig. 8A). As the L/V mutation has a minor impact
Fig. 7 (2R,3S)-7 does not perturb WT BET-dependent cells. Eﬀects of
compounds on viability of BET-dependent cell-lines MV4-11 & HL-60.
2462 | Chem. Sci., 2018, 9, 2452–2468 This journal is © The Royal Society of Chemistry 2018
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on uninhibited recovery times (Fig. S5†) the eﬀects of inhibition
on diﬀerent constructs can be reliably compared.
Our data shows that, for all BET proteins, inhibition of BD1
has a greater eﬀect than that of BD2 (Fig. 8B–E). Interestingly,
the degree to which BD1 is dominant varies between the BET
proteins. BD2 inhibition had no impact on BRDT (Fig. 8E), and
(2R,3S)-7 had the same eﬀect on both the LV/WT and LV/LV
constructs. These data are consistent with a model in which
BRDT BD2 is not involved in chromatin binding, a conclusion
recently drawn by Miller and colleagues.43 BRD4 (Fig. 8B) did
Fig. 8 Application of the bump-&-hole system to a biological question. (A–E) Eﬀects of 7 enantiomers on the ﬂuorescence recovery of GFP-
labelled full-length BET constructs in U2OS cells, following 0.5 s laser bleach event, at 2 mM SAHA and 0.03%DMSO. Compound concentration is
200 nM unless stated otherwise. Unpaired t tests compare the eﬀects of each compound to said construct's DMSO control. Results aremean and
SEM of 50 cells tested over 2 separate experiments. †–t1/2 could not be determined due to inhibition-induced aggregation. Statistical
signiﬁcance determined with two-tailed t tests: ns P > 0.05; *P # 0.05, **P # 0.01, ***P # 0.001, ****P < 0.0001.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2452–2468 | 2463
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see a small change in t1/2 in response to BD2 inhibition, sug-
gesting (alongside previous experiments from us10 and others42)
that it has a minor role in chromatin binding. Finally BRD3
(Fig. 8C) shows the greatest impact of BD2 inhibition, and
mutation of both bromodomains is necessary for full
displacement from chromatin, suggesting a much more
balanced mechanism of bromodomain:histone binding. We
cannot be certain of the role of BRD2 BD2 (Fig. 8D) as the WT/
LV construct shows no change in t1/2 but BD1 inhibition does
not match that of the double mutant. Inhibition of the double
mutant could not be quantied, as the GFP-BRD2 construct
aggregated in the nucleus. This phenomenon was shown to be
connected to strong inhibition and to occur with the WT
construct and hence not be due to any destabilizing eﬀect of the
L/V mutation (Fig. S13†). Inhibition-triggered aggregation of
bromodomain constructs has previously been observed.44
To provide additional functional insights into the individual
roles of BD1 vs. BD2 beyond chromatin binding, a luciferase
assay was developed to monitor the expression of NF-kB target
genes, inspired by work of Zou et al.45 Expression of our NF-kB-
controlled luciferase was signicantly increased by over-
expression of GFP-BRD4 (on top of endogenous BET protein).
This luciferase induction was maintained with L/V mutations
(but not L/A), consistent again with more WT-like functionality
of L/V compared to L/A (Fig. 9A).
Treatment of (2R,3S)-7 and (2R,3S)-8 against each GFP-BRD4
L/V construct showed that inhibiting either individual BD of
BRD4 strongly impacted on NF-kB signalling, matching that of
inhibiting both BDs (Fig. 9B). Together, the FRAP and luciferase
data are consistent with the BD2 having little role in chromatin
binding, but still being vital for initiating transcription and
regulating gene expression, at least in the case of BRD4 and NF-
kB.
Discussion
Through a variety of techniques we have optimized both the
biological and chemical aspects of our BET-bromodomain tar-
geting bump-&-hole system. From our library of bumped
compounds we have highlighted (2R,3S)-7 which shows high
potency and strong selectivity for our L/V mutation, which we
have shown to be more structurally and functionally conserva-
tive than the previous L/A mutation.
We applied our optimized system to address a biological
question – the relative importance of the BD1s and BD2s of BET
proteins to chromatin binding.10,42,43 By dosing a variety of GFP-
BET constructs in our FRAP assay we showed that, for all BET
proteins, chromatin binding is primarily inuenced by BD1s.
Furthermore we could show that the degree to which the BD1 is
dominant varies between BET proteins and that BRD3 is
sensitive to BD2 inhibition. Interestingly our GFP-BRDT
construct generates signicantly slower recovery times (t1/2 
1.5 s) when uninhibited. This could indicate BRDT being
a weaker binder of acetylated chromatin, or a result of U2OS not
presenting BRDT's preferred epigenetic marks. These observa-
tions show that when using this bump-&-hole system it may be
necessary to mutate both bromodomains to fully displace
a given BET protein. If the BD2s of certain BET proteins do not
primarily function through the binding of chromatin then an
alternate function could be the recognition and recruitment of
acetylated, non-histone proteins. Several such interactions have
been reported,46–49 such as an interaction between BRD4 BD2
and di-acetylated Twist.50 The unusual BD1/BD2 balance dis-
played by BRD3 suggests its chromatin and non-chromatin
mediated biological functions may also be atypical.
By combining our bump-&-hole system and a NF-kB lucif-
erase assay we were able to assess the importance of the BD1
and BD2 of BRD4 to initiating transcription and regulating gene
expression (for NF-kB target genes). Our data revealed that
BRD4 BD2 is still vital for transcription initiation, despite
having a minor role in chromatin binding. This suggests that
recruitment of non-histone proteins is also essential. This is
consistent with the model put forth by Shi et al.50 wherein BRD4
BD2 binds Twist, a transcriptional activator, giving the BRD4 –
P-TEFb – RNA Pol II complex specicity for WNT5A. One can
Fig. 9 BRD4 and NF-kB-target gene expression. Luminescence of
HEK cells transfected with GFP-labelled BRD4 constructs and a NF-
kB-RE/luc2P reporter plasmid. (A) Luminescence normalised to GFP
control. Statistical signiﬁcance indicators relate to WT BRD4. (B) Basal
luciferase expression (with GFP plasmid) subtracted as background.
Signal normalised to each construct's DMSO control. Results are mean
and standard error of six technical replicates spread over two inde-
pendent experiments. Statistical signiﬁcance determined with two-
tailed t tests: ns P > 0.05; *P# 0.05, **P# 0.01, ***P# 0.001, ****P <
0.0001.
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imagine that there are other non-histone proteins (NF-kB in our
example45) recognised by BRD4 BD2, and other BET BDs not
involved in chromatin binding, that can direct BET proteins to
up-regulate other specic sets of genes. In the future, a more
widespread and systematic investigation into such non-histone
BET binding partners could reveal much about how they func-
tion on a molecular level, and present new opportunities for
drug or chemical probe development.
Recently the results of BET-inhibitor clinical trials have
highlighted the risks of on-target toxicity, especially thrombo-
cytopenia.23,51–55 The BD2-selective RVX-208 (ref. 28) is the only
BET-inhibitor to progress to phase 3, hinting at reduced
toxicity.56 This low toxicity could be a result of the reduced role
of BD2s in chromatin binding through three potential routes.
As the BD2s are less important to chromatin binding RVX-208
may generate only partial BET inhibition and a greater thera-
peutic window. As the role of the BD2 diﬀers between BET
proteins this could generate some inter-protein selectivity for
BRD3 over BRD4, reducing any BRD4-mediated toxicity. Finally,
RVX-208may not function through chromatin displacement but
by blocking interactions between BD2s and non-histone
proteins (such as Twist) and hence act through a more
precise, less toxic, mechanism.
Through a combination of selectivity screens we show
(2R,3S)-7 to have almost no oﬀ-target inhibition. The only
signicant oﬀ-target is the melatonin receptor MT1. MT1 has
been shown to have a variety of functions,57 primarily taking
place in the CNS and regarding the circadian rhythm, which
should not complicate the use of (2R,3S)-7. Based on the results
of said selectivity screens, the observation of cytotoxicity in BET-
dependent AML cell-lines above 1 mM and our FRAP dose-
response experiments we recommend that, for cellular experi-
ments, a dosage of 100–500 nM is optimal, to allow for total or
near-total inhibition of L/V BET proteins while sparing the wild-
type.
Although we show how the current system can be used to
address biological questions, the investigation of more complex
physiological and disease-relevant functions, for example
comparing the genes regulated by each protein, will require the
development of isogenic cell-lines and model organisms
carrying the L/V mutation. Recent advances in the use of the
CRISPR/cas9 system58 as a gene-editing technology presents an
ideal opportunity to introduce single-point mutations into
a variety of cell-lines andmodel organisms, without introducing
exogenous BET genes that may not be regulated or post-
translationally processed correctly.
Our optimized bumped compounds could also provide
useful chemical tools for sophisticated or unconventional
chemical genetics experiments. Ethyl-amide containing
compounds (16, 17 & 21) could be converted into L/V-selective
alternatives to Bio-JQ1 (ref. 40) and a series of JQ1-based
cross-linking compounds used for protein pulldown and uo-
rescence microscopy.59 The 1,4-benzodiazepine scaﬀold used in
BET inhibitors has also been derivatized to create PROTAC
degraders32–35,37 and bivalent inhibitors,60 and such modica-
tions could be implemented in our bumped compounds.
Through optimizing our specic bump-&-hole system we
believe we have revealed some observations relevant to the
bump-&-hole technique in general. It is clear that any mutation
introduced to target proteins must be very subtle, as even the
relatively conservative L/A mutation had noticeable eﬀects on
BET bromodomain binding and function. Fortunately, major
mutations and large ‘holes’ are not required for selectivity, as
our L/V mutation allowed for over 100-fold selectivity despite
the removal of only one methyl group. By association, the
design of mutant-selective compounds should focus on minor
modications, and longer alkyl bumps can easily cause large
drops in potency. Large bumps will also increase the molecular
weight and log P of the inhibitor, leading to poorer DMPK
properties. Care should be taken with regard to bump place-
ment, as our compounds featured the bump on a exible side-
group which allowed for some residual WT binding. This could
be prevented by locking the bump in place, as we do with the
amide side-groups, or by placing the bump on a rigid part of the
scaﬀold. Interestingly, we show the potential of introducing
chemical modications that are not located near the bump or
mutation, as our best compounds contained a methoxy shi
modication quite distant to our alkyl bump and L/V hole.
Conclusions
In summary, we describe an iterative, step-wise and rational
optimization of the bump-&-hole approach for allele-selective
BET bromodomain inhibition, in both its biological and
chemical aspects, which has led to the development of a more
reliable and powerful system.
Through a three-stage process, several bumped analogues
were identied with high potency, selectivity for the L/V mutant
over WT bromodomains and desirable DMPK properties. This
culminated in our selection of enantiomerically-pure (2R,3S)-7
as a chemical probe targeting L/V BET bromodomains with
200 nM potency, >100-fold selectivity across the BET
subfamily and displaying an excellent DMPK prole.
This orthogonal (2R,3S)-7:L/V inhibitor:mutant pair was
validated through a number of in vitro and cellular experiments,
and then utilized to answer a biological question, revealing that
the BD1 of all BET proteins is more important to chromatin
binding than the BD2, albeit to varying degrees. Interestingly,
the BD2 of BRD4 was shown to still be essential for transcrip-
tion (with NF-kB target genes) highlighting the importance of
BD:non-histone protein interactions. We present this optimized
bump-&-hole system as a powerful and reliable tool for inves-
tigating the biological role of the BET proteins and for more
advanced target validation.
Crystal structure PDB codes
BRD2 BD2 L383V apo (5O38), in complex with compounds 3
(5O39), 4 (5O3A), 5 (5O3B), 7 (5O3C), 8 (5O3D), 16 (5O3E),
17(5O3F), 18 (5O3G) 21 (5O3H) and 24 (5O3I).
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